Aquestive Therapeutics (NASDAQ:AQST) will post its quarterly earnings results before the market opens on Wednesday, August 7th. Analysts expect Aquestive Therapeutics to post earnings of ($0.67) per share for the quarter. Aquestive Therapeutics has set its FY 2019 guidance at EPS.
Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.10). The firm had revenue of $12.64 million during the quarter, compared to analyst estimates of $10.66 million. On average, analysts expect Aquestive Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
NASDAQ AQST opened at $3.13 on Tuesday. The company has a market cap of $82.67 million and a P/E ratio of -1.12. The company has a current ratio of 1.89, a quick ratio of 1.71 and a debt-to-equity ratio of 4.23. The firm’s 50 day moving average is $4.12. Aquestive Therapeutics has a fifty-two week low of $2.96 and a fifty-two week high of $20.70.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.
See Also: Rule of 72
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.